Клаудиа Копперлэнд

Квалификация:
PhD Molecular and Cellular Biology, Tulane University

Область экспертизы:
Вирусология, Молекулярная биология, Молекулярная энтомология и паразитология, Биоинформатика, Биохимия.

Биография:

Dr. Claudia Copeland holds a PhD in molecular and cellular biology, specialising in parasitology and tropical medicine (Tulane University), and has completed postdoctoral fellowships in molecular entomology (United States Dept. of Agriculture, Agricultural Research Service) and computational genomics (University of Leipzig, Germany). Her research, which ranged from bench molecular biology and computer-based genetic studies to gathering fruit fly-infested guavas in Mexican cloud forest, includes molecular parasitology, retrotransposons/retroviruses, tropical medicine, parasite genetics, molecular evolution, molecular entomology, sex-ratio determination/parthenogenesis, noncoding RNA, and computational genomics. Dr Copeland has 5 years of professional scientific English editing experience (academic manuscripts, copy editing for journals, editing and content review for popular science websites and market research reports).

Кристофер Патил

Квалификация:
PhD Biochemistry and Cell Biology; University of California

Область экспертизы:
Онкология, Неврология, Биохимия белков, Иммунология, Микробиология, Биофизика.

Биография:

Dr Christopher Patil pursued a Ph.D. at the University of California-San Francisco, studying signal transduction in cellular stress responses. At UCSF, thesis work involved some of the earliest functional genomics studies to use expression profiling by microarrays. After a postdoctoral fellowship at the Lawrence Berkeley National Laboratory, he moved on to senior scientist positions at the Buck Institute for Research on Aging and most recently the Broad Institute of MIT and Harvard. Following his thesis work, his research career focused on the mechanisms of cellular senescence, the role of aging in cancer, and the transcriptional changes associated with neuronal aging. In collaboration with colleagues, he discovered that senescent cells secrete inflammatory factors that contribute to oncogenesis and age-related decline in tissue function, and revealed the molecular mechanisms that regulate this program of inflammatory gene expression.

Мери Питчер

Квалификация:
PhD, Cardiovascular, University of Sherbrooke, Canada

Область экспертизы:
Клеточная биология, Онкология, Молекулярная биология, Инфекционные заболевания, Пульмонология.

Биография:

Dr. Maryse Picher (Ph.D.) is a medical research scientist specialized on respiratory diseases, with 12 years of experience in drug discovery. During her appointment as principal investigator at the Cystic Fibrosis/Pulmonary Research and Treatment Center (NC), Dr. Picher discovered and modeled a new signaling pathway regulating airway clearance. Her activities also included consulting services to Inspire Pharmaceutical, which generated a patent and two publications. Currently, Dr. Picher is an independent consultant expert for CFRx and Flatley Venture Capital (FVC), both specialized in drug discovery for respiratory diseases. Her task is to provide advices on in vitro models and drug screening protocols, and to evaluate the scientific soundness of drugs selected for clinical trials by companies soliciting partnership with FVC. Dr. Picher published 75 scientific documents and presented over 35 lectures.

Джулия Рода

Квалификация:
PhD Cancer immunology, The Ohio State University

Область экспертизы:
Иммунология, Онкология, Молекулярная и клеточная биология.

Биография:

Dr Julie Roda's overall research interests lie in the immunosuppressive effects of cancer in the tumor microenvironment and the manner in which infiltrating immune cells can influence cancer growth and progression. As a graduate student at Ohio State, she worked to characterize the response of natural killer (NK) cells to anti-tumor antibodies such as trastuzumab (Herceptin), showing a vital role for NK cells in the response to tumor antibodies and initiating numerous clinical trials in which tumor antibodies were administered with NK cell-activating adjuvants. Dr Roda's post-doctoral research, also at Ohio State, focused on O2-dependent gene transcription and the regulation of angiogenesis by tumor-infiltrating myeloid cells. They identified the transcription factor HIF-2-alpha as an inhibitor of angiogenesis through its regulation of a soluble decoy VEGF receptor (sVEGFR-1), which acts as an endogenous inhibitor of VEGF, and developed small molecule inhibitors of the prolyl hydroxylases (the upstream activators of HIF-2-alpha) as potential cancer therapeutics to modulate the angiogenic activity of tumor macrophages.